Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Organogenesis Holdings Inc.

Get SEC filing alerts via email and in your feed for Organogenesis Holdings Inc.

ORGO

Organogenesis Holdings Inc.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. specializes in regenerative medicine and tissue-based products for advanced wound care, surgical, and sports medicine markets. Its core offerings include skin substitutes, placental allografts, and collagen biomaterials designed to promote healing of chronic and acute wounds. Serving hospitals, clinics, and surgical centers, the company leverages proprietary technologies, FDA-approved biologics, and a broad product pipeline to address growing healthcare needs driven by aging populations and chronic diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Organogenesis Holdings Inc.

1
1
Organogenesis Holdings Inc. Organogenesis Reports 57% Revenue Decline and $53.2 Million Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Organogenesis Holdings Inc. Organogenesis Holdings Reports 17% Revenue Growth to $563M in Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Organogenesis Holdings Inc. Organogenesis Holdings Reports 31% Revenue Growth to $150.9 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Organogenesis Holdings Inc. Organogenesis Reports Revenue Decline and Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Organogenesis Holdings Inc. Organogenesis Reports $86.7 Million Revenue in Q1 2025, Net Loss of $18.8 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Organogenesis Holdings Inc. Organogenesis Reports $482M Revenue for Fiscal Year 2024, Driven by Advanced Wound Care Growth

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Organogenesis Holdings Inc. Organogenesis Holdings Reports Mixed Q3 Results with Revenue Growth, Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments